Simulations Plus Uplisted to The Nasdaq Global Select Market®
Simulations Plus, Inc. (Nasdaq: SLP) announced that its common stock has been approved for trading on The Nasdaq Global Select Market effective May 13, 2021. This milestone reflects the company's successful growth investments that have enhanced its financial performance and global scale. CEO Shawn O’Connor highlighted that this step will increase visibility and liquidity for existing and future shareholders. Simulations Plus has been providing modeling and simulation solutions for over 25 years, serving clients in pharmaceutical and biotechnology sectors.
- Approval for trading on The Nasdaq Global Select Market enhances visibility and liquidity.
- Increased financial performance due to growth investments.
- Company serves clients in pharmaceutical, biotechnology, and other sectors for over 25 years.
- None.
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that its shares of common stock have been approved for trading on The Nasdaq Global Select Market® effective as of the market open on Thursday, May 13, 2021, and will continue trading under its current ticker symbol SLP.
“The growth investments we’ve made over the past few years have led to accelerated financial performance and increased the global scale of our business, enabling us to meet the requirements for The Nasdaq Global Select Market,” commented Shawn O’Connor, chief executive officer of Simulations Plus. “This achievement is a testament to the hard work of our employees and partners around the world, and we believe the opportunity for increased visibility and liquidity will benefit our existing loyal and future shareholders.”
About Simulations Plus, Inc.
Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005354/en/
FAQ
When did Simulations Plus (SLP) get approved for Nasdaq Global Select Market trading?
What does the Nasdaq Global Select Market approval mean for Simulations Plus (SLP)?
What is the significance of Simulations Plus (SLP) growing its financial performance?
